Crescent Biopharma (CBIO) investors back directors, auditor and annual say-on-pay
Filing Impact
Filing Sentiment
Form Type
8-K
Rhea-AI Filing Summary
Crescent Biopharma, Inc. reported the results of its annual general meeting of shareholders held on June 2, 2026. Shareholders elected Jonathan Violin, Ph.D. and Susan Moran, M.D., MSCE as Class II directors to serve until the 2029 annual general meeting.
Investors also ratified PricewaterhouseCoopers LLP as independent registered public accounting firm for the fiscal year ending December 31, 2026, and approved on a non-binding basis the compensation of named executive officers. Shareholders recommended holding future advisory votes on executive pay every year, and the Board agreed to follow an annual frequency.
Positive
- None.
Negative
- None.
8-K Event Classification
Item 5.07 — Submission of Matters to a Vote of Security Holders
1 item
Item 5.07
Submission of Matters to a Vote of Security Holders
Governance
Results of a shareholder vote on proposals at an annual or special meeting.
Key Figures
Ordinary shares outstanding on record date: 27,571,935 shares
Series A preferred shares outstanding: 2,890 shares
Votes for auditor ratification: 21,049,101 votes
+4 more
7 metrics
Ordinary shares outstanding on record date
27,571,935 shares
Issued and outstanding as of April 7, 2026 record date
Series A preferred shares outstanding
2,890 shares
Issued and outstanding as of April 7, 2026 record date
Votes for auditor ratification
21,049,101 votes
Ratification of PricewaterhouseCoopers LLP for FY ending December 31, 2026
Votes for say-on-pay
18,346,099 votes
Non-binding advisory approval of named executive officer compensation
Votes for 1-year say-on-pay frequency
18,644,881 votes
Advisory vote on frequency of future executive compensation votes
Votes for Jonathan Violin
2,890,000 votes
Election as Class II director, Proposal 1A
Votes for Susan Moran
21,401,136 votes
Election as Class II director, Proposal 1B
Key Terms
non-binding advisory basis, independent registered public accounting firm, broker non-votes, emerging growth company, +1 more
5 terms
non-binding advisory basis financial
"Proposal No. 3 - Approval, on a non-binding advisory basis, of the compensation of the Company’s named executive officers."
A non-binding advisory basis is guidance or a recommendation offered for informational purposes that does not create legal obligations or guarantees; recipients can accept, modify, or ignore it without contractual consequences. Investors should treat it like a weather forecast for planning—useful for forming expectations and assessing risk, but not a firm promise—so they should verify assumptions, seek confirming information, and avoid relying on it as the sole basis for investment decisions.
independent registered public accounting firm financial
"Ratification of the appointment of PricewaterhouseCoopers LLP as the Company’s independent registered public accounting firm for the fiscal year ending December 31, 2026."
An independent registered public accounting firm is an outside accounting company officially registered with the government regulator to examine and report on a public company's financial records and controls. Investors treat its reports like an impartial inspector’s certificate — they add credibility to financial statements, help spot errors or misleading claims, and reduce the risk that shareholders are relying on unchecked or biased numbers.
broker non-votes financial
"Votes FOR | Votes WITHHELD | Broker Non-Votes"
Broker non-votes occur when a brokerage firm is unable to vote on a shareholder’s behalf during a company election or decision because the shareholder has not given specific voting instructions, and the broker is not allowed or chooses not to vote on certain matters. They are important because they can affect the outcome of votes, especially when the results are close, by effectively reducing the total number of votes cast.
emerging growth company regulatory
"Emerging growth company o"
An emerging growth company is a recently public or smaller public firm that qualifies for temporary, lighter regulatory and disclosure rules to reduce the cost and effort of being public. For investors, it means the company may provide less historical financial detail and face fewer reporting requirements than larger firms, so it can grow more quickly but also carries higher uncertainty—like buying a promising early-stage product with fewer user reviews.
record date financial
"At the close of business on April 7, 2026, the record date for the Annual Meeting"
The record date is the specific day when a company determines which shareholders are eligible to receive a dividend or participate in an upcoming vote. It’s like a cutoff date; if you own the stock on that day, you get the benefits or voting rights. This date matters because it decides who qualifies for certain company benefits.
FAQ
Was Crescent Biopharma (CBIO) executive compensation approved at the 2026 meeting?
Yes, shareholders approved the non-binding advisory vote on named executive officer compensation. There were 18,346,099 votes for, 300,217 votes against, 876 abstentions and 2,403,515 broker non-votes on this say-on-pay proposal.
How often will Crescent Biopharma (CBIO) hold say-on-pay votes?
Shareholders recommended a one-year frequency for future advisory votes on executive compensation. The Board decided to hold these advisory votes every year until shareholders vote again on frequency or the Board changes this approach.